Who is sponsoring NCT05570942?

NCT05570942 is sponsored by National Taiwan University Hospital.

What drugs are being tested in NCT05570942?

Interventions in NCT05570942: Oral Lactobacillus rhamnosus TCELL-1.

What condition does NCT05570942 study?

NCT05570942 studies Staged III Colorectal Cancer Receiving Adjuvant Chemotherapy.

Is NCT05570942 still recruiting?

NCT05570942 is currently status unknown. Last updated 7 October 2022.

Last reviewed 2022-10-07 · How we verify

NCT05570942

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Oral Lactobacillus Rhamnosus TCELL-1 and Colorectal Cancer

Status unknown Phase 2 Last updated 7 October 2022

What this trial tests

Phase 2 trial testing Oral Lactobacillus rhamnosus TCELL-1 in Staged III Colorectal Cancer Receiving Adjuvant Chemotherapy in 56 participants. Status unknown.

Timeline

7 December 2021

Primary endpoint
31 December 2022

31 December 2022

Quick facts

Lead sponsor	National Taiwan University Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	other
Enrollment	56
Start date	7 December 2021
Primary completion	31 December 2022
Estimated completion	31 December 2022
Sites	1 location across Taiwan

Drugs / interventions tested

Oral Lactobacillus rhamnosus TCELL-1

Conditions studied

Staged III Colorectal Cancer Receiving Adjuvant Chemotherapy — all drugs for Staged III Colorectal Cancer Receiving Adjuvant Chemotherapy →

Sponsor

National Taiwan University Hospital

Who can join

20 and older, any sex, with Staged III Colorectal Cancer Receiving Adjuvant Chemotherapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Emerging evidences have shown that gut microbiota have played roles in the modulation of chemotherapy agents for cancer patients receiving chemotherapy. Probiotics are gut microbiota beneficial to human body. However, little was known about the role of probiotics for cancer patients receiving chemotherapy. Lactobacillus rhamnosus TCELL-1 is a kind of probiotics which were isolated from the gut mucosa of healthy Taiwanese. The aim of the study was to evaluate the effect of Lactobacillus rhamnosus TCELL-1 upon staged III colorectal cancer patients receiving adjuvant chemotherapy.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Probiotics, prebiotics, and postbiotics in health and disease.
Ji J, Jin W, Liu SJ, Jiao Z, et al · · 2023 · cited 198× · PMID 37929014 · DOI 10.1002/mco2.420
Exploring Therapeutic Advances: A Comprehensive Review of Intestinal Microbiota Modulators.
Pires L, González-Paramás AM, Heleno SA, Calhelha RC. · · 2024 · cited 13× · PMID 39200020 · DOI 10.3390/antibiotics13080720
Exploring the role of gut microbiota in colorectal liver metastasis through the gut-liver axis.
Liu QL, Zhou H, Wang Z, Chen Y. · · 2025 · cited 1× · PMID 40181829 · DOI 10.3389/fcell.2025.1563184

Verify or expand the search:

Other National Taiwan University Hospital trials

Trials by the same sponsor.

NCT06936917 — Timing for Computed Tomography and Post-Resuscitation Care on Short-Term Outcomes in Out-of-Hospital Cardiac Arrest · not yet recruiting
NCT05396222 — A Prospective Study of the Safety and Efficacy of 3D-printed Non-rigid Biomimetic Implant in Cervical and Thoracolumbar · NA · not yet recruiting
NCT07532356 — Integrating Tumor Genomics and Urinary Exosomal Proteomics to Establish a Multi-Layer Biomarker Framework for Early Risk · not yet recruiting
NCT07317310 — The NTU JO-SMART Study · NA · not yet recruiting
NCT07382024 — Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial Fibrillation · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05570942 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Taiwan University Hospital
Last refreshed: 7 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05570942.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing